Jazz Pharmaceuticals (JAZZ) Non-Current Deffered Revenue (2010 - 2022)

Jazz Pharmaceuticals' Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $116000.0 for Q3 2022.

• In Q3 2022, Non-Current Deffered Revenue fell 88.24% year-over-year to $116000.0; the TTM figure through Sep 2022 stood at $116000.0 (down 88.24% YoY), while the FY2021 annual figure was $463000.0, down 80.0% from the prior year.
• Non-Current Deffered Revenue for Q3 2022 stood at $116000.0, down from $231000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $13.6 million in Q1 2018, with the low at $116000.0 in Q3 2022.
• The 5-year median for Non-Current Deffered Revenue is $3.6 million (2020), against an average of $4.8 million.
• The sharpest annual moves came in 2019 and 2022: Non-Current Deffered Revenue plunged 38.41% in 2019, then slumped 88.24% in 2022.
• Jazz Pharmaceuticals' Non-Current Deffered Revenue stood at $9.6 million in 2018, then tumbled by 49.26% to $4.9 million in 2019, then tumbled by 52.38% to $2.3 million in 2020, then tumbled by 80.0% to $463000.0 in 2021, then tumbled by 74.95% to $116000.0 in 2022.
• Business Quant data shows JAZZ's Non-Current Deffered Revenue at $116000.0 in Q3 2022, $231000.0 in Q2 2022, and $347000.0 in Q1 2022.